Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus DONEPEZIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus DONEPEZIL HYDROCHLORIDE.
ADLARITY vs DONEPEZIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor